Cargando…

Early or deferred initiation of efavirenz during rifampicin‐based TB therapy has no significant effect on CYP3A induction in TB‐HIV infected patients

BACKGROUND AND PURPOSE: In TB‐HIV co‐infection, prompt initiation of TB therapy is recommended but anti‐retroviral treatment (ART) is often delayed due to potential drug–drug interactions between rifampicin and efavirenz. In a longitudinal cohort study, we evaluated the effects of efavirenz/rifampic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aklillu, Eleni, Zumla, Alimuddin, Habtewold, Abiy, Amogne, Wondwossen, Makonnen, Eyasu, Yimer, Getnet, Burhenne, Jürgen, Diczfalusy, Ulf
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Oxysterols, Lifelong Health and Therapeutics–Research Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8359173/ https://www.ncbi.nlm.nih.gov/pubmed/33155675 http://dx.doi.org/10.1111/bph.15309

Ejemplares similares

Pharmacogenetic & Pharmacokinetic Biomarker for Efavirenz Based ARV and Rifampicin Based Anti-TB Drug Induced Liver Injury in TB-HIV Infected Patients
por: Yimer, Getnet, et al.
Publicado: (2011)

Prevalence and risk factors for efavirenz-based antiretroviral treatment–associated severe vitamin D deficiency: A prospective cohort study
por: Nylén, Hanna, et al.
Publicado: (2016)

Impact of Population and Pharmacogenetics Variations on Efavirenz Pharmacokinetics and Immunologic Outcomes During Anti-Tuberculosis Co-Therapy: A Parallel Prospective Cohort Study in Two Sub-Sahara African Populations
por: Mugusi, Sabina, et al.
Publicado: (2020)

Efficacy and Safety of Antiretroviral Therapy Initiated One Week after Tuberculosis Therapy in Patients with CD4 Counts < 200 Cells/μL: TB-HAART Study, a Randomized Clinical Trial
por: Amogne, Wondwossen, et al.
Publicado: (2015)

Importance of Ethnicity, CYP2B6 and ABCB1 Genotype for Efavirenz Pharmacokinetics and Treatment Outcomes: A Parallel-Group Prospective Cohort Study in Two Sub-Saharan Africa Populations
por: Ngaimisi, Eliford, et al.
Publicado: (2013)

Constitutive androstane receptor and pregnane X receptor genotype influence efavirenz plasma concentration and CYP2B6 enzyme activity
por: Petros, Zelalem, et al.
Publicado: (2022)

Evaluation of Patterns of Liver Toxicity in Patients on Antiretroviral and Anti-Tuberculosis Drugs: A Prospective Four Arm Observational Study in Ethiopian Patients
por: Yimer, Getnet, et al.
Publicado: (2014)

The ratio of ursodeoxycholyltaurine to 7‐oxolithocholyltaurine serves as a biomarker of decreased 11β‐hydroxysteroid dehydrogenase 1 activity in mouse
por: Weingartner, Michael, et al.
Publicado: (2021)

Sex difference in flux of 27‐hydroxycholesterol into the brain
por: Parrado‐Fernandez, Cristina, et al.
Publicado: (2021)

HLA-B(*)57 Allele Is Associated with Concomitant Anti-tuberculosis and Antiretroviral Drugs Induced Liver Toxicity in Ethiopians
por: Petros, Zelalem, et al.
Publicado: (2017)

Genome-wide association and replication study of anti-tuberculosis drugs-induced liver toxicity
por: Petros, Zelalem, et al.
Publicado: (2016)

Anti-Tuberculosis Therapy-Induced Hepatotoxicity among Ethiopian HIV-Positive and Negative Patients
por: Yimer, Getnet, et al.
Publicado: (2008)

Copy Number Variation of Fc Gamma Receptor Genes in HIV-Infected and HIV-Tuberculosis Co-Infected Individuals in Sub-Saharan Africa
por: Machado, Lee R., et al.
Publicado: (2013)

Pharmacokinetics of Efavirenz 600mg in Combination with Rifampicin in Chinese HIV/TB Co-Infection Patients
por: Wang, Tongtong, et al.
Publicado: (2023)

CCL3L1 copy number, HIV load, and immune reconstitution in sub-Saharan Africans
por: Aklillu, Eleni, et al.
Publicado: (2013)

Effect of efavirenz-based ART on the pharmacokinetics of rifampicin and its primary metabolite in patients coinfected with TB and HIV
por: Sundell, Jesper, et al.
Publicado: (2021)

CYP3A and CYP2B6 Genotype Predicts Glucose Metabolism Disorder among HIV Patients on Long-Term Efavirenz-Based ART: A Case-Control Study
por: Tadesse, Wondmagegn Tamiru, et al.
Publicado: (2022)

Accelerating development of new shorter TB treatment regimens in anticipation of a resurgence of multi-drug resistant TB due to the COVID-19 pandemic
por: Tiberi, Simon, et al.
Publicado: (2021)

Explorative Analysis of Treatment Outcomes of Levofloxacin- and Moxifloxacin-Based Regimens and Outcome Predictors in Ethiopian MDR-TB Patients: A Prospective Observational Cohort Study
por: Sidamo, Temesgen, et al.
Publicado: (2021)

Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing rifampicin
por: Mugusi, Sabina, et al.
Publicado: (2018)

Early mortality during rifampicin-resistant TB treatment
por: Mohr-Holland, E., et al.
Publicado: (2022)

Pediatric delamanid treatment for children with rifampicin-resistant TB
por: Tyeku, N., et al.
Publicado: (2022)

Effect of Rumex Abyssinicus on preneoplastic lesions in dimethylhydrazine induced colon carcinogenesis in rats
por: Girma, Biniyam, et al.
Publicado: (2015)

Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adults
por: Uttayamakul, Sumonmal, et al.
Publicado: (2010)

Central Nervous System Tuberculosis (CNS-TB) in treated HIV-infected adults in Tikur Anbessa Specialized Hospital, Ethiopia: A cross sectional study
por: Ayele, Biniyam A., et al.
Publicado: (2021)

Genetic and non‐genetic factors influencing efavirenz population pharmacokinetics among human immunodeficiency virus‐1‐infected children in Ethiopia
por: Chala, Adugna, et al.
Publicado: (2023)

Development of a single-tube, low-cost, analytical process to extract, separate and determine efavirenz and rifampicin plasma concentrations in HIV/TB co-infected patients
por: Fox, D, et al.
Publicado: (2010)

CYP2J2(∗)7 Genotype Predicts Risk of Chemotherapy-Induced Hematologic Toxicity and Reduced Relative Dose Intensity in Ethiopian Breast Cancer Patients
por: Ahmed, Jemal Hussien, et al.
Publicado: (2019)

Diagnosis patterns for rifampicin-resistant TB after onset of COVID-19
por: Mohr-Holland, E., et al.
Publicado: (2021)

Anemia Is a Strong Predictor of Wasting, Disease Severity, and Progression, in Clinical Tuberculosis (TB)
por: Ashenafi, Senait, et al.
Publicado: (2022)

B in TB: B Cells as Mediators of Clinically Relevant Immune Responses in Tuberculosis
por: Rao, Martin, et al.
Publicado: (2015)

Predictors of Efavirenz Plasma Exposure, Auto-Induction Profile, and Effect of Pharmacogenetic Variations among HIV-Infected Children in Ethiopia: A Prospective Cohort Study
por: Chala, Adugna, et al.
Publicado: (2021)

Low isoniazid and rifampicin concentrations in TB/HIV co-infected patients in Uganda
por: Sekaggya Wiltshire, Christine, et al.
Publicado: (2014)

Investigation of the efficacy of the short regimen for rifampicin-resistant TB from the STREAM trial
por: Phillips, P. P. J., et al.
Publicado: (2020)

Sugar and sugar-free liquid formulations of delamanid for patients with rifampicin-resistant TB
por: Taneja, R., et al.
Publicado: (2023)

Implementation of evidence-based multiple focus integrated intensified TB screening to end TB (EXIT-TB) package in East Africa: a qualitative study
por: Isangula, Kahabi, et al.
Publicado: (2023)

Factors Associated with Mortality of TB/HIV Co-infected Patients in Ethiopia
por: Teklu, Alula M, et al.
Publicado: (2017)

Global Tuberculosis Report 2020 – Reflections on the Global TB burden, treatment and prevention efforts
por: Chakaya, Jeremiah, et al.
Publicado: (2021)

Vitamin D Status and Association of VDR Genetic Polymorphism to Risk of Breast Cancer in Ethiopia
por: Ahmed, Jemal Hussien, et al.
Publicado: (2019)

Short-term impact of celebrating the international clinical trial day: experience from Ethiopia
por: Fekadu, Abebaw, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_2tr6hs9fl4busabfmdr46fi466